Tempus Introduces its AI-enabled Care Pathway Intelligence Platform, Tempus Next
April 16 2024 - 9:30AM
Business Wire
Tempus, a leader in artificial intelligence and precision
medicine, is introducing Tempus Next, a care pathway intelligence
platform. By harnessing the power of AI, Tempus Next identifies
care gaps and equips clinicians with actionable insights at the
point of care, supporting access to the most up-to-date,
guideline-directed treatments.
Tempus Next is designed to accelerate the adoption of precision
medicine and enhance patient outcomes. The solution integrates
seamlessly with EMRs in order to analyze a comprehensive suite of
data—including clinical notes, molecular information, and
imaging—to pinpoint deviations from care guidelines. Participating
health systems receive regular updates, enabling them to maintain
high care quality standards and track patient outcomes
effectively.
“Given that Tempus is now connected in near real time to more
than 50% of all oncologists in the U.S., we have the ability to
deploy AI solutions at a scale that has historically not been
possible,” said Eric Lefkofsky, CEO and Founder of Tempus. “The
increasing complexity of guidelines and the compounding data that
physicians need to access in order to treat their patients has
created a growing number of care gaps. Next is designed to help
close those gaps by seamlessly notifying care teams when a
guideline or standard is not being followed, so that every patient
has access to the personalized attention and treatment they
deserve.”
Tempus has extensive experience delivering care pathway
intelligence in cardiology, with over sixty care pathway
intelligence algorithms in cardiovascular disease currently
deployed across more than eighty hospitals. Tempus Next has
expanded into oncology, starting with lung cancer and breast
cancer, with a number of leading institutions.
“We are at the cusp of a healthcare transformation, and with
Tempus Next, we anticipate setting a new standard for patient
care,” said Andrew Parchman, MD, Precision Oncology Medical
Director, Medical Oncologist, TriHealth Cancer Institute. “This
platform’s ability to notify us of care gaps and guide
evidence-based decisions in real-time aligns perfectly with our
mission to deliver personalized, proactive treatment to every
patient.”
“The Tempus Next platform has revolutionized patient care by
delivering actionable insights in real time,” said Abhinav B.
Chandra, MD, Medical Director, Yuma Regional Medical Center Cancer
Center. “These insights enable timely adjustments to patient
management, ensuring precision and responsive healthcare.”
About Tempus
Tempus is a technology company advancing precision medicine
through the practical application of artificial intelligence in
healthcare. With one of the world’s largest libraries of multimodal
data, and an operating system to make that data accessible and
useful, Tempus provides AI-enabled precision medicine solutions to
physicians to deliver personalized patient care and in parallel
facilitates discovery, development and delivery of optimal
therapeutics. The goal is for each patient to benefit from the
treatment of others who came before by providing physicians with
tools that learn as the company gathers more data. For more
information, visit tempus.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240416014992/en/
Erin Carron, erin.carron@tempus.com